Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus
AssigneeElanco Animal Health Ireland Limited
InventorJohannes Wilhelmus J. Thuring
Life of this patent
Estimating the term…
Abstract
This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.
Claims14
1-11. (canceled)
A method of treating or preventing feline immunodeficiency virus in a feline animal comprising administering to said feline animal a therapeutically effective amount of a compound of formula (I), including the stereochemically isomeric forms thereof, or a pharmaceutically acceptable salt thereof,
- wherein
- W is —NH—, —N(CH3)— or piperazine,
- X is a bond, —C(═O)— or —S(═O)2—,
- Y is C3-7alkylene, and
- Z is —NH—C(═O)— or —O—;
- and optionally one or more anti-viral agents.
A product comprising a compound of the formula
- wherein
- W is —NH—, —N(CH3)— or piperazine,
- X is a bond, —C(═O)— or —S(═O)2—,
- Y is C3-7alkylene, and
- Z is —NH—C(═O)— or —O—;
- and an anti-viral agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prophylaxis of feline immunodeficiency virus.
A product comprising a compound of the formula
- wherein
- W is —NH—, —N(CH3)— or piperazine,
- X is a bond, —C(═O)— or —S(═O)2—,
- Y is C3-7alkylene, and
- Z is —NH—C(═O)— or —O—;
- and an anti-viral agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prophylaxis of feline immunodeficiency virus.
Dependencies are inferred from the claim text.